243 related articles for article (PubMed ID: 34778941)
21. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
22. Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients.
Nydegger A; Novak U; Kronig MN; Legros M; Zeerleder S; Banz Y; Bacher U; Pabst T
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885182
[TBL] [Abstract][Full Text] [Related]
23. Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk.
Lyu C; Cui R; Wang J; Mou N; Jiang Y; Li W; Deng Q
Front Oncol; 2021; 11():706087. PubMed ID: 34395279
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
25. Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy.
Di Rocco A; Cuneo A; Di Rocco A; Merli F; De Luca G; Petrucci L; Ansuinelli M; Penna D; Rotondo F; Rigolin GM; Giaimo M; Re F; Farcomeni A; Martelli M; Foà R
Leuk Lymphoma; 2021 Apr; 62(4):828-836. PubMed ID: 33274677
[TBL] [Abstract][Full Text] [Related]
26. The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy.
Garcia-Recio M; Wudhikarn K; Pennisi M; Alonso-Trillo R; Flynn J; Shouval R; Afuye AO; Silverberg ML; Batlevi CW; Dahi P; Devlin S; Giralt SA; Halton E; Ruiz J; Maloy M; Mead E; Palomba ML; Santomasso B; Sauter CS; Scordo M; Shah GL; Perales MA
Transplant Cell Ther; 2021 Mar; 27(3):233-240. PubMed ID: 33781518
[TBL] [Abstract][Full Text] [Related]
27. Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.
Rentsch V; Seipel K; Banz Y; Wiedemann G; Porret N; Bacher U; Pabst T
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626120
[TBL] [Abstract][Full Text] [Related]
28. Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma.
Snyder S; Chung KC; Jun MP; Gitlin M
Adv Ther; 2021 Sep; 38(9):4659-4674. PubMed ID: 34302277
[TBL] [Abstract][Full Text] [Related]
29. Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.
Zhu W; Tao S; Miao W; Liu H; Yuan X
Front Immunol; 2022; 13():894787. PubMed ID: 35757723
[TBL] [Abstract][Full Text] [Related]
30. Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient.
Hu L; Wu F; Wang H; Zhu W; Wang J; Yu F; Zhai Z
Front Immunol; 2021; 12():665230. PubMed ID: 33953727
[TBL] [Abstract][Full Text] [Related]
31. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Jeyakumar N; Smith M
Front Immunol; 2022; 13():887866. PubMed ID: 35663947
[TBL] [Abstract][Full Text] [Related]
32. Transdifferentiation of diffuse large B-cell lymphoma to a poorly differentiated neoplasm following CAR T-cell therapy.
Padmanabha N; Weinstock MJ; Xu S; Lepe M; Garrett LA; Kappes UP; Michaels PD
J Hematop; 2024 Jun; ():. PubMed ID: 38878262
[TBL] [Abstract][Full Text] [Related]
33. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.
Chakraborty R; Sidana S; Shah GL; Scordo M; Hamilton BK; Majhail NS
Biol Blood Marrow Transplant; 2019 May; 25(5):e155-e162. PubMed ID: 30500439
[TBL] [Abstract][Full Text] [Related]
34. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
Avivi I; Perry C; Segman Y; Amit O; Bar-On Y; Katz OB; Gold R; Ribakovsky E; Avigdor A; Vainstein V; Goldschmidt N; Ringelstein-Harlev S; Horowitz NA; Gutwein O; Gurion R; Itchaki G; Abadi U; Nemets A; Sofer O; Vezker M; Tadmor T; Dally N; Filanovsky K; Leiba M; Sarid N; Benyamini N; Luttwak E; Herishanu Y; Ram R
Ann Hematol; 2022 Apr; 101(4):755-762. PubMed ID: 35083525
[TBL] [Abstract][Full Text] [Related]
35. Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting.
Thakkar A; Cui Z; Peeke SZ; Shah N; Pradhan K; Lombardo A; Khatun F; Mustafa J; De Castro A; Gillick K; Joseph F; Naik A; Rahman S; D'Aiello A; Elkind R; Sakalian S; Fehn K; Wright K; Abreu M; Townsend-Nugent L; Chambers N; Mathew R; Binakaj D; Nelson R; Palesi C; Paroder M; Uehlinger J; Wang Y; Shi Y; Zang X; Wang H; Nishimura C; Ren X; Steidl UG; Gritsman K; Janakiram M; Kornblum N; Derman O; Mantzaris I; Shastri A; Bartash R; Puius Y; McCort M; Goldfinger M; Bachier-Rodriguez L; Verma A; Braunschweig I; Sica RA
Stem Cell Investig; 2021; 8():18. PubMed ID: 34631871
[TBL] [Abstract][Full Text] [Related]
36. [
Cohen D; Luttwak E; Beyar-Katz O; Hazut Krauthammer S; Bar-On Y; Amit O; Gold R; Perry C; Avivi I; Ram R; Even-Sapir E
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):953-962. PubMed ID: 34480603
[TBL] [Abstract][Full Text] [Related]
37. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study.
Huang C; Wu L; Liu R; Li W; Li Z; Li J; Liu L; Shan B
Ann Transl Med; 2020 Sep; 8(17):1048. PubMed ID: 33145267
[TBL] [Abstract][Full Text] [Related]
39. CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement.
Shumilov E; Boyadzhiev H; Mazzeo P; Akhoundova D; Daskalakis M; Novak U; Lenz G; Bacher U; Pabst T
Hemasphere; 2023 Dec; 7(12):e984. PubMed ID: 38044958
[TBL] [Abstract][Full Text] [Related]
40. Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?
Saifi O; Kharfan-Dabaja MA; Zeidan YH; Peterson J; Rule WG; Lester SC; Hoppe BS
Int J Part Ther; 2020; 7(1):13-20. PubMed ID: 33094131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]